Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving PremarketBenzinga • 17 days ago
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of...
Share to Feed
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30...
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They...
It has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares have added about 2% in that time frame, underperforming the S&P 500.Will the recent positive trend...
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President...
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen...
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic...
NEXLETOL (bempedoic acid) Tablet
New Labels Expand Treatable Population to ~70 Million Patients in U.S. First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients...
Esperion Therapeutics, Inc. (NASDAQ:ESPR Free Report) Equities research analysts at Zacks Research dropped their Q1 2024 earnings estimates for Esperion Therapeutics in a report...
Connor Clark & Lunn Investment Management Ltd. grew its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR Free Report) by 120.1% during the third quarter, according to the company in its...